$1.2 million for preventing and managing chronic diseases in Quebec - The
FRQS, MSSS and Pfizer announce funding for two chronic disease research
MONTREAL, March 5, 2013 /CNW Telbec/ - The Fonds de recherche du Québec -
Santé (FRQS), in partnership with the Quebec Ministry of Health and Social
Services (MSSS) and the pharmaceutical company Pfizer Canada, announces the
second series of projects chosen under the Pfizer-FRQS-MSSS Chronic Disease
Created thanks to an investment of $5 million from Pfizer Canada, this
FRQS-coordinated research grant program is aimed at evaluating and funding
chronic disease prevention and management initiatives, fostering, where
appropriate, their implementation throughout Quebec, and making our healthcare
system more efficient.
Two of the projects submitted were recommended for funding, namely, those of
the CSSS de Chicoutimi and the CSSS de l'Ouest-de-l'Île. This announcement
represents investments totalling more than $1.2 million over the next two
All the projects submitted to the Pfizer-FRQS-MSSS Chronic Disease Fund had to
be in line with the Ministry of Health and Social Services' chronic disease
goals, be primary-care initiatives for promoting the integration of chronic
disease prevention and management, and focus on changing clinical practices.
In accordance with the FRQS's current rules and procedures, the applications
were examined by a scientific review committee consisting of experts from
scientific and clinical settings.
Primary-care management of vulnerable chronic disease patients
Spearheaded by the CSSS de Chicoutimi and the CSSS Lac-Saint-Jean-Est in Alma,
the first project, named V1SAGES, is aimed at implementing and evaluating a
primary-care case-management and self-management intervention for highly
vulnerable chronic disease patients. To this end, an intervention will be
implemented in four family medicine groups (FMGs) in Saguenay-Lac-Saint-Jean.
The intervention will involve nurse-led case management and self-management
support meetings. This project will receive a grant of $624,972 over two years.
An integrated, primary-care chronic pain prevention and management network
The goal of the second project, headed by the CSSS de l'Ouest-de-l'Île, is to
implement and evaluate an integrated, primary-care chronic pain prevention and
management network. The objective is to expand an integrated, patient-centred,
interdisciplinary program for the prevention and management of subacute low
back pain in which the intensity of the intervention is tailored to the
patient's health. More than 1200 patients will be followed on the territories
of two Montreal CSSSs (Ouest-de-l'Île, Cavendish), one CSSS in Abitibi and
one in the Montérégie. This project will receive a grant of $621,250 over
"We're very happy to support these innovative projects, thanks to the
collaboration of MSSS and Pfizer Canada. Chronic diseases pose a significant
challenge to all of Quebec society. These unique projects, which include both
a clinical component and an evaluative research component, are providing an
opportunity to recognize and disseminate original chronic disease prevention
and management initiatives throughout Quebec," says Dr. Renaldo Battista,
Scientific Director of the Fonds de recherche du Québec - Santé.
"Pfizer Canada is firmly committed to discovering new ways to improve people's
health and, as such, is proud to partner with the FRQS and MSSS to stimulate
innovation and the sharing of good practices and tools created to facilitate
primary care for Quebec's chronic disease patients," notes Dr. Bernard
Prigent, Vice-President and Medical Director of Pfizer Canada.
About the Fonds de recherche du Québec - Santé (FRQS)
The mission of the Fonds de la recherche du Québec - Santé (FRQS), which
reports to the Minister of Higher Education, Research, Science and Technology,
is to support health research in order to foster the wellness of Quebecers.
Its mandate is to promote and financially support this research, to share
knowledge and train researchers, as well as to establish partnerships
necessary for the development of Quebec's research and innovation system and
advance the research internationally. For additional information visit:
About Pfizer Canada Inc.
Pfizer Canada Inc. is the Canadian division of Pfizer Inc., one of the world's
leading biopharmaceutical companies. Pfizer Canada is one of the largest
contributors to health research in Canada. Pfizer's diversified healthcare
portfolio includes human and animal biologics, small-molecule medicines and
vaccines, nutritional products and many of the world's best-known consumer
Every day, Pfizer Canada employees work to advance wellness, prevention,
treatments and cures that challenge the most feared diseases of our time. We
apply science and our global resources to improve the health and well-being of
Canadians at every stage of life. Our commitment is reflected in everything
Pfizer does, from our disease awareness initiatives to our community
partnerships, to our belief that it takes more than medication to be truly
healthy. To learn more about Pfizer's More Than Medication philosophy and
programs, visit morethanmedication.ca. To learn more about Pfizer Canada,
Michelle Dubuc FRQS 514-873-2114, ext.1235 firstname.lastname@example.org
Julie-Catherine Racine Pfizer Canada 1-866-973-4937
SOURCE: Fonds de recherche du Québec - Santé
To view this news release in HTML formatting, please use the following URL:
CO: Fonds de recherche du Québec - Santé
NI: HEA MTC HEA
-0- Mar/05/2013 12:00 GMT
Press spacebar to pause and continue. Press esc to stop.